MARKET

REPL

REPL

Replimune Group
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.26
-1.41
-4.19%
After Hours: 32.26 0 0.00% 16:00 09/24 EDT
OPEN
33.19
PREV CLOSE
33.67
HIGH
33.25
LOW
32.21
VOLUME
191.38K
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
20.40
MARKET CAP
1.51B
P/E (TTM)
-17.5355
1D
5D
1M
3M
1Y
5Y
Replimune Group Inc (REPL) COO Colin Love Sold $936,900 of Shares
GuruFocus News · 09/18 12:15
BRIEF-Replimune Group Inc - Restructuring Of Operations Has Resulted In Elimination Of Role Of Chief Medical Officer, Effective Immediately
reuters.com · 08/25 20:43
Bvf Inc Buys GH Research PLC, argenx SE, Syndax Pharmaceuticals Inc, Sells , Ionis ...
GuruFocus News · 08/24 19:38
10 Biggest Price Target Changes For Monday
Telsey Advisory Group boosted the price target for Burlington Stores, Inc. (NYSE: BURL) from $380 to $400. Burlington fell 0.4% to close at $347.52 on Friday.
Benzinga · 08/23 11:54
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $49
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $55 to $49.
Benzinga · 08/23 10:15
SVB Leerink Adjusts Price Target on Replimune to $49 From $55, Maintains Outperform Rating
MT Newswires · 08/23 09:38
Insider Trends: Replimune Group Insider Continues 90-Day Selling Trend
MT Newswires · 08/18 21:16
We're Not Worried About Replimune Group's (NASDAQ:REPL) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 08/09 13:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPL. Analyze the recent business situations of Replimune Group through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPL stock price target is 55.22 with a high estimate of 64.00 and a low estimate of 49.00.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 36.19M
% Owned: 77.37%
Shares Outstanding: 46.77M
TypeInstitutionsShares
Increased
38
3.66M
New
15
920.23K
Decreased
38
3.69M
Sold Out
12
569.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Dieter Weinand
President/Director
Robert Coffin
Chief Executive Officer/Director
Philip Astley-Sparke
Chief Financial Officer/Treasurer
Jean Franchi
Chief Operating Officer
Colin Love
Other
Pamela Esposito
Other
Tanya Lewis
Other
Sushil Patel
Independent Director
Kapil Dhingra
Independent Director
Hyam Levitsky
Independent Director
Paolo Pucci
Independent Director
Jason Rhodes
Independent Director
Joseph Slattery
Independent Director
Sander Slootweg
Independent Director
Otello Stampacchia
No Data
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1, RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Webull offers kinds of Replimune Group Inc stock information, including NASDAQ:REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.